Angiotensin I and angiotensin II concentrations and their ratio in catecholamine-resistant vasodilatory shock von Bellomo, Rinaldo, Wunderink, Richard G., Szerlip, Harold, English, Shane W., Busse, Laurence W., Deane, Adam M., Khanna, Ashish K., McCurdy, Michael T., Ostermann, Marlies, Young, Paul J., Handisides, Damian R., Chawla, Lakhmir S., Tidmarsh, George F., Albertson, Timothy E.

Volltext

ACE inhibitors and angiotensin receptor blockers differentially alter the response to angiotensin II treatment in vasodilatory shock von Leisman, Daniel E, Handisides, Damian R, Busse, Laurence W, Chappell, Mark C, Chawla, Lakhmir S, Filbin, Michael R, Goldberg, Marcia B, Ham, Kealy R, Khanna, Ashish K, Ostermann, Marlies, McCurdy, Michael T, Adams, Christopher D, Hodges, Tony N, Bellomo, Rinaldo

Volltext

Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug von Hu, Jinsong, Handisides, Damian R., Van Valckenborgh, Els, De Raeve, Hendrik, Menu, Eline, Vande Broek, Isabelle, Liu, Qian, Sun, Jessica D., Van Camp, Ben, Hart, Charles P., Vanderkerken, Karin

Volltext

A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma von Laubach, Jacob P, Liu, Chia-Jen, Raje, Noopur S, Yee, Andrew J, Armand, Philippe, Schlossman, Robert L, Rosenblatt, Jacalyn, Hedlund, Jacquelyn, Martin, Michael, Reynolds, Craig, Shain, Kenneth H, Zackon, Ira, Stampleman, Laura, Henrick, Patrick, Rivotto, Bradley, Hornburg, Kalvis T V, Dumke, Henry J, Chuma, Stacey, Savell, Alexandra, Handisides, Damian R, Kroll, Stew, Anderson, Kenneth C, Richardson, Paul G, Ghobrial, Irene M

Volltext

Angiotensin II treatment is associated with improved oxygenation in ARDS patients with refractory vasodilatory shock von Leisman, Daniel E., Handisides, Damian R., Chawla, Lakhmir S., Albertson, Timothy E., Busse, Laurence W., Boldt, David W., Deane, Adam M., Gong, Michelle N., Ham, Kealy R., Khanna, Ashish K., Ostermann, Marlies, McCurdy, Michael T., Thompson, B. Taylor, Tumlin, James S., Adams, Christopher D., Hodges, Tony N., Bellomo, Rinaldo

Volltext

Phase I study of evofosfamide, an investigational hypoxia‐activated prodrug, in patients with advanced leukemia von Badar, Talha, Handisides, Damian R., Benito, Juliana M., Richie, Mary Ann, Borthakur, Gautam, Jabbour, Elias, Harutyunyan, Karine, Konoplev, Sergej, Faderl, Stefan, Kroll, Stew, Andreeff, Michael, Pearce, Tillman, Kantarjian, Hagop M., Cortes, Jorge E., Thomas, Deborah A., Konopleva, Marina

Volltext

Synergistic induction of apoptosis in multiple myeloma cells by bortezomib and hypoxia-activated prodrug TH-302, in vivo and in vitro von Hu, Jinsong, Van Valckenborgh, Els, Xu, Dehui, Menu, Eline, De Raeve, Hendrik, De Bruyne, Elke, De Bryune, Elke, Xu, Song, Van Camp, Ben, Handisides, Damian, Hart, Charles P, Vanderkerken, Karin

Volltext

Renin and Survival in Patients Given Angiotensin II for Catecholamine-Resistant Vasodilatory Shock A Clinical Trial von Bellomo, Rinaldo, Forni, Lui G., Busse, Laurence W., McCurdy, Michael T., Ham, Kealy R., Boldt, David W., Hastbacka, Johanna, Khanna, Ashish K., Albertson, Timothy E., Tumlin, James, Storey, Kristine, Handisides, Damian, Tidmarsh, George F., Chawla, Lakhmir S., Ostermann, Marlies

Volltext

Regional differences in the treatment of refractory vasodilatory shock using Angiotensin II in High Output Shock (ATHOS-3) data von Abril, Maria K., Khanna, Ashish K., Kroll, Stew, McNamara, Connor, Handisides, Damian, Busse, Laurence W.

Volltext

A Phase 1/2 Study of evofosfamide, A Hypoxia-Activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma von Laubach, Jacob P., Liu, Chia-Jen, Raje, Noopur S., Yee, Andrew J., Armand, Philippe, Schlossman, Robert L., Rosenblatt, Jacalyn, Hedlund, Jacquelyn, Martin, Michael, Reynolds, Craig, Shain, Kenneth H., Zackon, Ira, Stampleman, Laura, Henrick, Patrick, Rivotto, Bradley, Hornburg, Kalvis T.V., Dumke, Henry J., Chuma, Stacey, Savell, Alexandra, Handisides, Damian R., Kroll, Stew, Anderson, Kenneth C., Richardson, Paul G., Ghobrial, Irene M.

Volltext

Final Results of a Phase 1/2 Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of Evofosfamide, a Hypoxia-Activated Prodrug, and Dexamethasone with or wi... von Laubach, Jacob P., Raje, Noopur, Yee, Andrew J., Armand, Philippe, Schlossman, Robert L., Rosenblatt, Jacalyn, Martin, Michael G., Reynolds, Craig, Shain, Kenneth H., Zackon, Ira, Stampleman, Laura V., Lai, Emily, Caola, Aaron M., Cappuccio, Joseph M., Rivotto, Bradley, Reyes, Kaitlen, Savell, Alexandra, Henrick, Patrick, Pearce, Tillman, Handisides, Damian, Kroll, Stew, Anderson, Kenneth C., Richardson, Paul G., Ghobrial, Irene M.

Volltext

Preliminary safety and efficacy of evofosfamide (TH-302), an investigational hypoxia-activated prodrug, combined with bortezomib and dexamethasone in patients with relapsed/refract... von Laubach, Jacob, Raje, Noopur S., Yee, Andrew Jenho, Armand, Philippe, Schlossman, Robert L., Rosenblatt, Jacalyn, Hedlund, Jacquelyn Ann, Martin, Michael Gary, Reynolds, Craig H., Shain, Kenneth H., Zackon, Ira, Stampleman, Laura, Boswell, Erica, Chuma, Stacey, Liguori, Rebecca, Handisides, Damian, Kroll, Stew, Anderson, Kenneth Carl, Richardson, Paul G., Ghobrial, Irene M.

Volltext

Leukemia Microenvironment and Pathologic Hypoxia: Sensitivity to Hypoxia-Activated Cytotoxin TH-302 von Benito, Juliana M, Andrei, Volgin Y, Chen, Ye, Hongbo, Lu, Shi, Yuexi, McQueen, Teresa, Zweidler-McKay, Patrick A, Handisides, Damian R, Hart, Charles, Andreeff, Michael, Konopleva, Marina

Volltext

A Phase 1 Study Of TH-302, An Investigational Hypoxia-Targeted Drug, In Patients With Advanced Leukemias von Konopleva, Marina, Handisides, Damian R, Richie, Mary Ann, Benito, Juliana M, Borthakur, Gautam, Jabbour, Elias J., Faderl, Stefan H., Cortes, Jorge E., Kroll, Stewart, Andreeff, Michael, Kantarjian, Hagop M, Thomas, Deborah A.

Volltext

Phase 1 Study Of TH-302, An Investigational Hypoxia-Targeted Drug, and Dexamethasone In Patients With Relapsed/Refractory Multiple Myeloma von Ghobrial, Irene M., Laubach, Jacob P., Raje, Noopur, Armand, Philippe, Schlossman, Robert L., Boswell, Erica N, Hanlon, Courtney, Chuma, Stacey, Handisides, Damian R, Kroll, Stewart, Anderson, Kenneth C., Richardson, Paul G.

Volltext

A Phase 1/2 Trial of TH-302 and Dexamethasone without or with Bortezomib (TBorD) in Patients with Relapsed/Refractory Multiple Myeloma von Laubach, Jacob P., Raje, Noopur S., Yee, Andrew J., Armand, Philippe, Schlossman, Robert L., Rosenblatt, Jacalyn, Matous, Jeffrey, Hedlund, Jacquelyn, Martin, Michael G, Reynolds, Craig, Shain, Kenneth H., Zackon, Ira, Stampleman, Laura V., Boswell, Erica N, Chuma, Stacey, Liguori, Rebecca, Mar, Stephanie, Handisides, Damian, Kroll, Stew, Anderson, Kenneth C., Richardson, Paul G., Ghobrial, Irene M.

Volltext

Phase I study of TH-302, an investigational hypoxia-targeted drug, and dexamethasone in patients with relapsed/refractory multiple myeloma von Ghobrial, Irene M., Laubach, Jacob, Armand, Philippe, Boswell, Erica, Hanlon, Courtney, Chuma, Stacey, Chu, Esther Dawn, Handisides, Damian, Kroll, Stew, Hickingbottom, Barbara, Anderson, Kenneth Carl, Richardson, Paul Gerard Guy

Volltext

Preliminary safety and efficacy of TH-302, an investigational hypoxia-targeted drug, and dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RR MM) von Laubach, Jacob, Raje, Noopur S., Armand, Philippe, Schlossman, Robert L., Rosenblatt, Jacalyn, Matous, Jeffrey, Hedlund, Jacquelyn Ann, Martin, Michael Gary, Reynolds, Craig H., Shain, Kenneth H., Zackon, Ira, Stampleman, Laura, Boswell, Erica, Chuma, Stacey, Liguori, Rebecca, Handisides, Damian, Kroll, Stew, Anderson, Kenneth Carl, Richardson, Paul G., Ghobrial, Irene M.

Volltext

Phase I study of TH-302, a hypoxia-activated cytotoxic prodrug, in subjects with advanced leukemias von Konopleva, Marina, Handisides, Damian, Lorente, Gustavo A., Benito, Juliana M., Richie, Mary Ann, Borthakur, Gautam, Jabbour, Elias, Faderl, Stefan, Cortes, Jorge E., Kroll, Stewart, Andreeff, Michael, Kantarjian, Hagop, Thomas, Deborah A.

Volltext

Abstract 4641: Hypoxia activated pro-drug TH-302 induces hypoxia-dependent anti-leukemia activity in vitro and in vivo von Benito, Juliana M., Lu, Hongbo, Shi, Yuexi, Jacamo, Rodrigo O., McQueen, Teresa J., Konoplev, Sergej, Bueso-Ramos, Carlos, Zweidler-McKay, Patrick, Handisides, Damian, Hart, Charles P., Andreeff, Michael, Konopleva, Marina

Volltext